ARCHIVES

Regulatory Approvals: FDA expanded the approved use of Cyramza to include metastatic NSCLC

This article is from The Cancer Letter archive.

Vol. 40 No. 47 | December 19, 2014

Download PDF Visit The Full Archive

Related Articles

DCPC Board Approves Concepts for $28.5 Million Polyp Trial, Other Nutrition Related Studies

May 19, 1989

Rosenberg’s Latest Results: 22% Response Seen With LAK/IL-2, 13% With High Dose IL-2 Alone

April 10, 1987

Evidence Links Anemia Drugs With Leukemic Transformation

December 28, 2007

Moloney Out As Viral Oncology Chief, Names “Acting Assistant Director” Of NCI By Upton

January 6, 1978

Coalition On Smoking Or Health to Launch Effort at $5 Tax Increase

July 3, 1992

Behavior Scientists To Discuss Cancer Patient Rehabilitation

January 17, 1975